Prognostic markers in bladder cancer: a contemporary review of the literature.
OBJECTIVE
We provide a contemporary review of bladder tumor markers and summarize their role as prognostic indicators.


METHODS
A comprehensive review of the literature on prognostic markers for transitional cell carcinoma of the bladder was performed.


RESULTS
Intense research efforts are being made to identify and characterize better various bladder cancers and their true biological potential. The need to predict which superficial tumors will recur or progress and which invasive tumors will metastasize has led to the identification of a variety of potential prognostic markers. Blood group antigens, tumor associated antigens, proliferating antigens, oncogenes, peptide growth factors and their receptors, cell adhesion molecules, tumor angiogenesis and angiogenesis inhibitors, and cell cycle regulatory proteins have recently been identified. The potential clinical applications of these tumor markers are under active investigation. Recent attention has focused on which tumor markers may predict the responsiveness of a particular bladder cancer to systemic chemotherapy.


CONCLUSIONS
At present conventional histopathological evaluation of bladder cancer (tumor grade and stage) cannot predict accurately the behavior of most bladder tumors. With a better understanding of the cell cycle, and cell to cell and cell to extracellular matrix interactions as well as improved diagnostic techniques (immunohistochemistry), progress is being made to identify and characterize other potential prognostic markers for transitional cell carcinoma of the bladder. The ultimate goal is to develop reliable prognostic markers that will accurately predict not only the course but also the response of a tumor to therapy. This information may then be used to dictate more aggressive treatment for tumors that are likely to progress and less aggressive treatment for those that are unlikely to progress. In the future these biological markers may also be used in gene therapy for the treatment of bladder cancer.
Department of Urology, Kenneth Norris, Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, USA.
J P
JP
Stein
G D
GD
Grossfeld
D A
DA
Ginsberg
D
D
Esrig
J A
JA
Freeman
A J
AJ
Figueroa
D G
DG
Skinner
R J
RJ
Cote
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002295:Carcinoma, Transitional Cell / Q000235:genetics / Q000276:immunology / Q000473:pathology; D015815:Cell Adhesion Molecules; D018797:Cell Cycle Proteins; D004815:Epidermal Growth Factor; D005544:Forecasting; D006801:Humans; D009389:Neovascularization, Pathologic; D009857:Oncogenes / Q000235:genetics; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D015815:Cell Adhesion Molecules; D018797:Cell Cycle Proteins; D004815:Epidermal Growth Factor